Recent News Releases
For investor-related news, see our ASX releases on our parent company's website: CSL.com.
Researchers Decipher a New Way that Immune Cells Detect Infections and Cancers
Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference
Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
King of Prussia, Pa.
HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
King of Prussia, Pa.
CSL Continues to Advance R&D Capabilities
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing
Harvard Business Review Names Paul Perreault Among Best Performing CEOs in the World
King of Prussia, Pa.
Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings
CSL Behring Continues to Deliver on its Promise to Alpha1 Patients at the 29th Annual European Respiratory Society Congress
• Focuses on Patients Through Disease Awareness Support Activities
• Hosts Patient-Focused Symposium on Alpha 1 Management
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted
CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting
- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address the unique needs of CIDP patients.
- Presentations include new analysis from the PATH (Polyneuropathy and Treatment with Hizentra) study, the largest clinical trial in CIDP.
Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders
Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May
CSL Names Paul McKenzie as Chief Operating Officer
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]
New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients
Global Biotherapeutics Leader CSL Behring Opens Regional Headquarters at Dubai Science Park
Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Japan’s Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®
CSL Behring Extends Support of World Federation of Hemophilia Programs
Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness
CSL Named One of the Best Employers in the US for Diversity
Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019
Global Biotech Leader CSL to Present at J.P. Morgan Healthcare Conference on Wednesday, January 9
CSL announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference.
CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal
Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.
New Study Finds Significantly Greater Costs Associated with Multi-Vessel Disease in Medicare Patients Compared to those with Single Vessel Disease following an Acute Myocardial Infarction
Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
Science Center and Biotech Leader CSL Behring Partner to Accelerate Academic Research in the Search for New Medicines and Possible Cures
Partnership to identify and help commercialize potential new medicines at research and academic institutions across the Greater Philadelphia region
CSL Behring to Feature Secondary Immunodeficiency Symposium at the 2018 Meeting of the European Society for Immunodeficiencies (ESID)
ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency
Resources for Media
Logos, Design Guidelines and more. (Registration required)
|See how we are Driven by Our Promise in our 16-page Corporate Brochure.|
Want to know more about how we are sharing stories of biotech's promise?Read Vita
For any CSL Plasma corporate or donation inquiries, please refer to the CSL Plasma website for more information.